Blog

CH Trading Group will serve as exclusive territories distributor in the Middle East and North Africa countries with US $105 million minimum purchase commitment.

07 Mar

SEC FIlings

Annual report for year ending December 31, 2022

March 7, 2023
Posted by Ulisses

03 Mar

SEC FIlings

General statement of acquisition of beneficial ownership

March 3, 2023
Posted by Ulisses

01 Mar

SEC FIlings

Current report

March 1, 2023
Posted by Jitendra

27 Feb

Press Release

Scilex Holding Company announces the commercial launch of ELYXYB^TM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

February 27, 2023
Posted by Jitendra

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market...

Post-Effective amendments for registration statement

Post-Effective amendments for registration statement

Post-Effective amendments for registration statement

Annual Report to Security Holders

Other definitive proxy statements

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

Annual report for year ending December 31, 2022

General statement of acquisition of beneficial ownership

Current report

Scilex Holding Company announces the commercial launch of ELYXYB^TM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

Henry Ji, PhD

Stephen Ma

Dorman Followwill

Alexander Wu, PhD

Jay Chun, MD, PhD